Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Laura Mezquita, Isabel Preeshagul, Edouard Auclin, Diana Saravia, Lizza Hendriks, Hira Rizvi, Wungki Park, Ernest Nadal, Patricia Martin-Romano, Jose C. Ruffinelli, Santiago Ponce, Clarisse Audigier-Valette, Simona Carnio, Felix Blanc-Durand, Paolo Bironzo, Fabrizio Tabbo, Maria Lucia Reale, Silvia Novello, Matthew D. Hellmann, Peter SawanJeffrey Girshman, Andrew J. Plodkowski, Gerard Zalcman, Margarita Majem, Melinda Charrier, Marie Naigeon, Caroline Rossoni, AnnaPaola Mariniello, Luis Paz-Ares, Anne Marie Dingemans, David Planchard, Nathalie Cozic, Lydie Cassard, Gilberto Lopes, Nathalie Chaput, Kathryn Arbour, Benjamin Besse*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalEuropean Journal of Cancer
Volume151
DOIs
Publication statusPublished - Jul 2021

Keywords

  • dNLR
  • Neutrophils
  • Immunotherapy
  • NSCLC
  • Biomarker
  • CELL
  • NEUTROPHILS
  • BIOMARKERS
  • INHIBITORS
  • NIVOLUMAB
  • DOCETAXEL
  • MARKERS

Cite this